Join P95 Julius Clinical at the European Society of Cardiology Congress 2026 in Munich from August 28-31, 2026.

Meet our cardiometabolic experts at the 2026 ESC Congress to discover how P95 Julius Clinical supports efficient, high-quality clinical trials across complex cardiometabolic and renal indications. Our team partners with sponsors to navigate the unique challenges of cardiometabolic drug development, delivering tailored strategies that accelerate timelines while maintaining scientific rigor.

Catch Rick on ESC TV

We’re proud to share that Rick Grobbee will host the ESC TV Day in Focus session on Sunday, 30 August 2026, from 18:45 to 19:10 on the ESC TV Stage.

Join Rick as he recaps the day’s most important congress highlights and key scientific developments from ESC Congress 2026.

Learn more about the session →

Let’s Meet in Munich!

Connect with our team at the event to discuss how we can support your next cardiometabolic or renal clinical trial.

Name(Required)

Advancing CVRM Clinical Development with Confidence

P95 Julius Clinical offers comprehensive support across all phases of clinical development. With deep expertise across cardiovascular, metabolic, and renal diseases, we help bring innovative therapies to patients faster. From protocol development to study execution, we provide a fully integrated approach designed to optimize outcomes at every stage.

Explore our cardiometabolic and renal expertise.

Why P95 Julius Clinical?

Cardiometabolic and renal trials present distinct challenges, from complex endpoints and patient variability to recruitment and retention barriers. P95 Julius Clinical combines scientific expertise with operational precision to address these challenges effectively.

With our strong global network and experienced in-house teams, we deliver customized solutions aligned with your development goals, ensuring high-quality data and reliable study execution.

Our expertise includes:

  • MASH / MASLD
  • Obesity
  • Cardiovascular disease
  • Hypercholesterolemia
  • Rare metabolic diseases
  • Renal indications
  • Diabetes and hypertension
  • Real-world evidence and hybrid trial strategies